Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

Overview of attention for article published in Lancet Oncology, February 2016

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news: 32 news outlets
policy: 1 policy source
twitter: 28 X users

patent: 13 patents
facebook: 2 Facebook pages

Citations

dimensions_citation: 547 Dimensions

Readers on

mendeley: 422 Mendeley

Summary News Policy documents X Patents Facebook Dimensions citations

So far, Altmetric has seen 2 policy documents that reference this research output.

Keytruda for Non-Small Cell Lung Cancer (Second Line or Beyond) – Details

Cited by Canadian Agency for Drugs and Technologies in Health on 01 Jun 2023

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

Programmed Death Ligand 1 (PD-L1) Testing for Pembrolizumab Effectiveness: Clinical Evidence

Cited by Canadian Agency for Drugs and Technologies in Health on 03 Jun 2016

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.